Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBenedito Mauro Rossi

About this trial

This study is being conducted to better understand how pancreatic cancer behaves during treatment and how we can improve methods for monitoring disease progression. The research aims to determine whether small molecules present in the blood, called miRNAs, can help doctors assess whether the treatment is working or needs adjustment. With this, we hope to make cancer monitoring less invasive and more precise, allowing patients to receive more personalized and effective treatments.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients diagnosed with metastatic PDAC;

Patients who will start treatment with FOLFIRINOX;

18 years or older;

Who agree to participate in the study by signing the Informed Consent Form;

Disqualifiers

Patients who have previously undergone chemotherapy, whether neoadjuvant, adjuvant, or any prior first-line treatment;

Patients who do not meet the minimum criteria to receive the proposed regimen, such as those with hyperbilirubinemia, those who are not candidates due to age or performance status deterioration;

Trial population

Patients diagnosed with metastatic PDAC of both sexes, aged 18 years or older, who will start treatment with FOLFIRINOX at BP - A Beneficência Portuguesa de São Paulo.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

60 Participants
are grouped into 2 trial groups
Group A: Non-responder
Group B: Responder

Trial outcomes

Primary outcomes

1

Response to treatment

Response to FOLFIRINOX treatment after 4 cycles of therapy.

Time frame
After 4 cycle of therapy (each cycle is 15 days)
2

Response to treatment

Response to FOLFIRINOX treatment after 8 cycles of therapy.

Time frame
After the 8 cycle of therapy (each cycle is 15 days)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Benedito Mauro Rossi

Lead sponsor

Beneficência Portuguesa de São Paulo

Sponsor institution